Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
Front Neurosci ; 17: 1304440, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38144211

RESUMEN

The brain cortex is the structure that is typically injured in traumatic brain injury (TBI) and is anatomically connected with other brain regions, including the striatum and hypothalamus, which are associated in part with motor function and the regulation of body temperature, respectively. We investigated whether a TBI extending to the striatum could affect peripheral and core temperatures as an indicator of autonomic thermoregulatory function. Moreover, it is unknown whether thermal modulation is accompanied by hypothalamic and cortical monoamine changes in rats with motor function recovery. The animals were allocated into three groups: the sham group (sham), a TBI group with a cortical contusion alone (TBI alone), and a TBI group with an injury extending to the dorsal striatum (TBI + striatal injury). Body temperature and motor deficits were evaluated for 20 days post-injury. On the 3rd and 20th days, rats were euthanized to measure the serotonin (5-HT), noradrenaline (NA), and dopamine (DA) levels using high-performance liquid chromatography (HPLC). We observed that TBI with an injury extending to the dorsal striatum increased core and peripheral temperatures. These changes were accompanied by a sustained motor deficit lasting for 14 days. Furthermore, there were notable increases in NA and 5-HT levels in the brain cortex and hypothalamus both 3 and 20 days after injury. In contrast, rats with TBI alone showed no changes in peripheral temperatures and achieved motor function recovery by the 7th day post-injury. In conclusion, our results suggest that TBI with an injury extending to the dorsal striatum elevates both core and peripheral temperatures, causing a delay in functional recovery and increasing hypothalamic monoamine levels. The aftereffects can be attributed to the injury site and changes to the autonomic thermoregulatory functions.

2.
Curr Neuropharmacol ; 21(10): 2110-2125, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37326113

RESUMEN

The Coronavirus disease 2019 (COVID-19) affects several tissues, including the central and peripheral nervous system. It has also been related to signs and symptoms that suggest neuroinflammation with possible effects in the short, medium, and long term. Estrogens could have a positive impact on the management of the disease, not only due to its already known immunomodulator effect, but also activating other pathways that may be important in the pathophysiology of COVID-19, such as the regulation of the virus receptor and its metabolites. In addition, they can have a positive effect on neuroinflammation secondary to pathologies other than COVID-19. The aim of this study is to analyze the molecular mechanisms that link estrogens with their possible therapeutic effect for neuroinflammation related to COVID-19. Advanced searches were performed in scientific databases as Pub- Med, ProQuest, EBSCO, the Science Citation index, and clinical trials. Estrogens have been shown to participate in the immune modulation of the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition to this mechanism, we propose that estrogens can regulate the expression and activity of the Angiotensin-converting enzyme 2 (ACE2), reestablishing its cytoprotective function, which may be limited by its interaction with SARS-CoV-2. In this proposal, estrogens and estrogenic compounds could increase the synthesis of Angiotensin-(1-7) (Ang-(1-7)) that acts through the Mas receptor (MasR) in cells that are being attacked by the virus. Estrogens can be a promising, accessible, and low-cost treatment for neuroprotection and neuroinflammation in patients with COVID-19, due to its direct immunomodulatory capacity in decreasing cytokine storm and increasing cytoprotective capacity of the axis ACE2/Ang (1-7)/MasR.


Asunto(s)
COVID-19 , Humanos , SARS-CoV-2/metabolismo , Enzima Convertidora de Angiotensina 2/metabolismo , Sistema Renina-Angiotensina/fisiología , Peptidil-Dipeptidasa A/metabolismo , Enfermedades Neuroinflamatorias , Estrógenos/uso terapéutico , Neuroprotección , Factores Inmunológicos/farmacología , Factores Inmunológicos/uso terapéutico
3.
Int J Mol Sci ; 24(4)2023 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-36834984

RESUMEN

The ongoing pandemic of COVID-19 has caused more than 6.7 million tragic deaths, plus, a large percentage of people who survived it present a myriad of chronic symptoms that last for at least 6 months; this has been named as long COVID. Some of the most prevalent are painful symptoms like headache, joint pain, migraine, neuropathic-like pain, fatigue and myalgia. MicroRNAs are small non-coding RNAs that regulate genes, and their involvement in several pathologies has been extensively shown. A deregulation of miRNAs has been observed in patients with COVID-19. The objective of the present systematic review was to show the prevalence of chronic pain-like symptoms of patients with long COVID and based on the expression of miRNAs in patients with COVID-19, and to present a proposal on how they may be involved in the pathogenic mechanisms of chronic pain-like symptoms. A systematic review was carried out in online databases for original articles published between March 2020 to April 2022; the systematic review followed the PRISMA guidelines, and it was registered in PROSPERO with registration number CRD42022318992. A total of 22 articles were included for the evaluation of miRNAs and 20 regarding long COVID; the overall prevalence of pain-like symptoms was around 10 to 87%, plus, the miRNAs that were commonly up and downregulated were miR-21-5p, miR-29a,b,c-3p miR-92a,b-3p, miR-92b-5p, miR-126-3p, miR-150-5p, miR-155-5p, miR-200a, c-3p, miR-320a,b,c,d,e-3p, and miR-451a. The molecular pathways that we hypothesized to be modulated by these miRNAs are the IL-6/STAT3 proinflammatory axis and the compromise of the blood-nerve barrier; these two mechanisms could be associated with the prevalence of fatigue and chronic pain in the long COVID population, plus they could be novel pharmacological targets in order to reduce and prevent these symptoms.


Asunto(s)
COVID-19 , Dolor Crónico , MicroARNs , Síndrome Post Agudo de COVID-19 , Humanos , Dolor Crónico/genética , COVID-19/complicaciones , COVID-19/genética , MicroARNs/genética , Síndrome Post Agudo de COVID-19/genética
4.
Antioxidants (Basel) ; 11(10)2022 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-36290695

RESUMEN

Obesity remains a global health problem. Chronic low-grade inflammation in this pathology has been related to comorbidities such as cognitive alterations that, in the long term, can lead to neurodegenerative diseases. Neuroinflammation or gliosis in patients with obesity and type 2 diabetes mellitus has been related to the effect of adipokines, high lipid levels and glucose, which increase the production of free radicals. Cerebral gliosis can be a risk factor for developing neurodegenerative diseases, and antioxidants could be an alternative for the prevention and treatment of neural comorbidities in obese patients. AIM: Identify the immunological and oxidative stress mechanisms that produce gliosis in patients with obesity and propose antioxidants as an alternative to reducing neuroinflammation. METHOD: Advanced searches were performed in scientific databases: PubMed, ProQuest, EBSCO, and the Science Citation index for research on the physiopathology of gliosis in obese patients and for the possible role of antioxidants in its management. CONCLUSION: Patients with obesity can develop neuroinflammation, conditioned by various adipokines, excess lipids and glucose, which results in an increase in free radicals that must be neutralized with antioxidants to reduce gliosis and the risk of long-term neurodegeneration.

5.
Pharmaceuticals (Basel) ; 15(6)2022 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-35745676

RESUMEN

The disease caused by SARS-CoV-2 is still considered a global pandemic. Transdermal patches (TP) with immunoregulators such as estrogen and progesterone compounds could be a feasible option to treat COVID-19 because of their accessibility and relative safety. The objective of the current study was to evaluate the additional treatment with norelgestromin and ethinylestradiol in TP on the clinical and biochemical evolution of COVID-19 patients. The present is a clinical-trial pilot study that included subjects diagnosed with COVID-19, randomized into two groups; the experimental Evra® TP (norelgestromin 6 mg and ethinylestradiol 0.60 mg) was administered such that it was applied on arrival and replaced at day 8 and day 15. The control continued with the conventional COVID-19 treatment protocol. A blood sample was taken each week in order to evaluate relevant biochemical parameters, clinical signs, and evolution. In total, 44 subjects participated in this study, 30 in the experimental group and 14 in the control group. Both groups were homogeneous in terms of age and comorbidities. The experimental group had a significantly lower hospital stay (p = 0.01), high flow supplemental oxygen (p = 0.001), mechanical ventilation (p = 0.003), and intubation (p = 0.01), and the oxygen saturation significantly increased (p = 0.01) in comparison with control group when patients were exposed to room air. A decrease in ferritin (p < 0.05) was observed, with no significant increase in ESR (p > 0.05), D dimer (p > 0.05) and platelets (p > 0.05) in an auto-controlled analysis in the experimental group. Norelgestromin and ethinylestradiol TP could be a safe and effective treatment for moderate and severe COVID-19 patients.

6.
Curr Top Med Chem ; 22(16): 1326-1345, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35382723

RESUMEN

The global pandemic caused by the SARS-CoV-2 virus began in early 2020 and is still present. The respiratory symptoms caused by COVID-19 are well established. However, neurological manifestations that may result from direct or indirect neurological damage after SARS-CoV-2 infection have been reported frequently. The main proposed pathophysiological processes leading to neurological damage in COVID-19 are cerebrovascular disease and indirect inflammatory/ autoimmune origin mechanisms. A growing number of studies confirm that neuroprotective measures should be maintained in COVID-19 patients. On the other hand, cannabinoids have been the subject of various studies that propose them as potentially promising drugs in chronic neurodegenerative diseases due to their powerful neuroprotective potential. In this review, we addresses the possible mechanism of action of cannabinoids as a neuroprotective treatment in patients infected by SARS-CoV-2. The endocannabinoid system is found in multiple systems within the body, including the immune system. Its activation can lead to beneficial results, such as a decrease in viral entry, a reduction of viral replication, and a reduction of pro-inflammatory cytokines such as IL-2, IL-4, IL-6, IL-12, TNF-α, or IFN-c through CB2R expression induced during inflammation by SARS-CoV-2 infection in the central nervous system.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Cannabinoides , Fármacos Neuroprotectores , Cannabinoides/farmacología , Cannabinoides/uso terapéutico , Humanos , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico , Pandemias , SARS-CoV-2
7.
Heliyon ; 7(3): e06466, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33748503

RESUMEN

The aging process is characterized by a gradual impairment generally caused by oxidative stress and, more specifically, sleep deprivation, which induces oxidative stress in the brain. The objective of this study was to assess the effect of three types of paradoxical sleep deprivation (PSD): 96 h of PSD (96PSD group); 192 h of PSD (192PSD group); 192 h of PSD followed by a recovery period of 20 days (192PSD + Recovery group) on an oral glucose tolerance test (OGTT), lipid peroxidation (LPO), and superoxide dismutase (SOD) and catalase (CAT) activities in the liver and pancreas of young (3-month-old) and adult (14-month-old) rats. The 96PSD and 192PSD groups of young rats showed lower glucose levels on the OGTT than the control group. In the adult rats, only the 96PSD group had lower glucose levels than the control group. However, the areas under the curve for the young and adult 192 and 192PSD + Recovery groups showed significant differences. Both LPO and SOD increased in the 192PSD and 192PSD + Recovery groups, but CAT decreased in the liver of young rats in the 192PSD group. Regarding the pancreas, LPO and SOD levels increased after 96 h of PSD. In adult animals, CAT decreased in the liver after 96 and 192 h of PSD, while LPO and SOD increased in the pancreas of the 192PSD and PSD + Recovery groups. Differences in the SOD and CAT activities in the liver and SOD activities in the pancreas were also observed between the young and adult rats and maintained across all the PSD groups. In conclusion, PSD induced differential responses that appeared to depend on the duration of the induced condition, the animals' age, and the tissue analyzed. It was found that adult rats were more susceptible to the effects of PSD than young rats.

8.
Arch Physiol Biochem ; 127(4): 337-343, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31291139

RESUMEN

AIM: The purpose of this work was to identify and measure catecholamines, their metabolites, and the gene expression of catecholamine receptors in osteosarcoma tissue. MATERIALS AND METHODS: The levels of 3,4-dihydroxyphenylacetic acid, norepinephrine, serotonin, and 5-hydroxyindoleacetic acid in cancer tissue and in adjacent and non-oncological bone tissue were analysed by high-performance liquid chromatography, and the gene expression of catecholamine receptors and of dopamine ß-hydroxylase, monoaminoxidase, ki67, and Runx2 in the osteosarcoma tissue, tissue adjacent to the tumour, non-oncological bone, and human brain tissue was analysed by RT-PCR. RESULTS: We found significantly higher levels of 3,4-dihydroxyphenylacetic acid and norepinephrine in the cancer sample than in adjacent and non-oncological bone. We found that ß-adrenergic receptors and dopaminergic receptors, dopamine ß-hydroxylase, ki67, Runx2, and serotonergic receptor gene expression were significantly higher in tumour tissue than in adjacent and non-oncological bone. CONCLUSION: Catecholamines and their receptors could be potential molecular markers for osteosarcoma progression.


Asunto(s)
Neoplasias Óseas/patología , Catecolaminas/metabolismo , Regulación de la Expresión Génica , Metaboloma , Osteosarcoma/patología , Receptores de Catecolaminas/metabolismo , Anciano , Neoplasias Óseas/genética , Neoplasias Óseas/metabolismo , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Osteosarcoma/genética , Osteosarcoma/metabolismo , Receptores de Catecolaminas/genética
9.
Curr Med Chem ; 28(15): 2996-3009, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-32767912

RESUMEN

BACKGROUND: Botulinum toxin type A (BoNT-A) is widely employed for cosmetic purposes and in the treatment of certain diseases such as strabismus, hemifacial spasm and focal dystonia among others. BoNT-A effect mainly acts at the muscular level by inhibiting the release of acetylcholine at presynaptic levels consequently blocking the action potential in the neuromuscular junction. Despite the great progress in approval and pharmaceutical usage, improvement in displacing BoNT-A to other pathologies has remained very limited. Patients under diagnosis of several types of cancer experience pain in a myriad of ways; it can be experienced as hyperalgesia or allodynia, and the severity of the pain depends, to some degree, on the place where the tumor is located. Pain relief in patients diagnosed with cancer is not always optimal, and as the disease progresses, transition to more aggressive drugs, like opioids is sometimes unavoidable. In recent years BoNT-A employment in cancer has been explored, as well as an antinociceptive drug; experiments in neuropathic, inflammatory and acute pain have been carried out in animal models and humans. Although its mechanism has not been fully known, evidence has shown that BoNT-A inhibits the secretion of pain mediators (substance P, Glutamate, and calcitonin gene related protein) from the nerve endings and dorsal root ganglion, impacting directly on the nociceptive transmission through the anterolateral and trigeminothalamic systems. AIM: The study aimed to collect available literature regarding molecular, physiological and neurobiological evidence of BoNT-A in cancer patients suffering from acute, neuropathic and inflammatory pain in order to identify possible mechanisms of action in which the BoNT-A could impact positively in pain treatment. CONCLUSION: BoNT-A could be an important neo-adjuvant and coadjuvant in the treatment of several types of cancer, to diminish pro-tumor activity and secondary pain.


Asunto(s)
Toxinas Botulínicas Tipo A , Dolor en Cáncer , Neoplasias , Animales , Toxinas Botulínicas Tipo A/uso terapéutico , Humanos , Hiperalgesia , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , Nocicepción , Dolor
10.
Acta méd. costarric ; 62(3)sept. 2020.
Artículo en Español | LILACS, SaludCR | ID: biblio-1383337

RESUMEN

Resumen En el contexto de la enseñanza de la farmacología y como parte de la formación médica, la simulación clínica mediante diversos dispositivos permite recrear la experiencia clínica sin necesidad de exponer a los pacientes, contribuye a mejorar el desarrollo de habilidades para la práctica clínica, y provee un ambiente seguro y controlado para la utilización de los medicamentos y la evaluación clínica de sus efectos. Otras ventajas tienen relación con el desarrollo del trabajo en equipo y del pensamiento crítico en el estudiante. Se considera que la simulación clínica es una técnica muy valiosa por su amplia utilidad didáctica; se integra como parte sustantiva de las actividades que se implementan para la enseñanza de la farmacología a los estudiantes de la carrera de Medicina, de la Universidad de Costa Rica.


Abstract In the context of pharmacology education and as part of medical training, clinical simulation using various devices allows recreating the clinical experience without exposing patients, contributes to improving the development of skills for clinical practice and provides a safe and controlled environment for the use of drugs and the clinical evaluation of their effects. Other advantages are related to the development of teamwork and critical thinking in the student. Currently, clinical simulation is considered to be a very valuable technique due to its wide didactic utility, it is integrated as a substantive part of the activities that are implemented to teach pharmacology to students of Medicine at the University of Costa Rica.


Asunto(s)
Farmacología , Educación Médica , Entrenamiento Simulado
11.
Odontología (Ecuad.) ; 22(1): 21-35, 2020.
Artículo en Español, Inglés, Portugués | LILACS | ID: biblio-1050376

RESUMEN

En implantología oral, ha sido motivo de investigación y constante evolución la interfase implante-pilar, princi-palmente desde el punto de vista biomecánico y biológico. Objetivo: Valorar el espacio o "gap" en la interfase implante-pilar en implantes de conexión hexagonal interna y externa por medio de microscopía electrónica de barrido (MEB). Materiales y Métodos: Estudio in vitro en 24 implantes (Bionnovation®) divididos en dos gru-pos (n=12): conexión hexagonal interna y externa. Para el experimento, se atornillaron pilares rectos con 30N de torque. A su vez 6 implantes por grupo se sometieron a 500000 ciclos de carga dinámica; posteriormente, se evaluó por MEB el espacio de la interfase implante pilar en 3 puntos de todas las muestras, las medias de los resultados de cada espécimen se respaldaron en tablas de Excel y se analizaron en el programa BioEstat 5.3. Resultados: Mediante test T para muestras independientes, con una significancia del 95%, se encontró una diferencia muy significativa luego de la aplicación de la carga dinámica en los implantes de hexágono ex-terno (p= 0.0002). En los implantes de hexágono interno también existió diferencia estadística (p= 0.03). Entre los implantes de hexágono externo e interno existieron diferencias muy significativas en la precisión del ajuste en la interfase implante pilar antes y después de la aplicación de las cargas dinámicas (p= <0.0001 y p= 0.0003 respectivamente). Conclusiones: Las cargas dinámicas aumentaron significativamente la discrepan-cia en la conexión implante-pilar de los implantes de hexágono externo e interno (p= < 0.05); adicionalmente, la distancia del "gap" fue mayor para los implantes de hexágono externo en contraste con los implantes de Hexágono Interno antes y después de la carga dinámica, siendo muy significativo (p= < 0.0003).


In oral implantology, the implant-pillar interface has been a subject of research and constant evolution, mainly from the biomechanical and biological point of view. Objective: To assess the gap in the implant-abutment interface in internal and external hexagonal connection implants by means of scanning electron microscopy (SEM). Materials and Methods: In vitro study in 24 implants (Bionnovation®) divided into two groups (n = 12): internal and external hexagonal connection. For the experiment, straight pillars with 30N of torque were screwed. In turn, 6 implants per group underwent 500,000 cycles of dynamic loading; Subsequently, the space of the pillar implant interface at 3 points of all samples was evaluated by MEB, the means of the results of each specimen were supported in Excel tables and analyzed in the BioEstat 5.3 program. Results: Using a T test for independent samples, with a significance of 95%, a very significant difference was found after the application of the dynamic load in the external hexagon implants (p = 0.0002). In the internal hexagon implants there was also a statistical difference (p = 0.03). Between the external and internal hexagon implants there were very significant differences in the accuracy of the adjustment in the abutment implant interface before and after the application of the dynamic loads (p = <0.0001 and p = 0.0003 respectively). Conclusions: Dynamic loads significantly increased the discrepancy in the implant-abutment connection of the external and internal hexa-gon implants (p = <0.05); additionally, the gap distance was greater for external hexagon implants in contrast to Internal Hexagon implants before and after dynamic loading, being very significant (p = <0.0003).


Na implantologia oral, a interface implante-pilar tem sido objeto de pesquisa e evolução constante, principal-mente do ponto de vista biomecânico e biológico. Objetivo: Avaliar o espaço ou "gap" na interface implan-te-pilar em implantes de conexão hexagonal interna e externa por meio de microscopia eletrônica de varre-dura (MEV). Materiais e Métodos: Estudo in vitro em 24 implantes (Bionnovation®) divididos em dois grupos (n = 12): conexão hexagonal interna e externa. Para o experimento, pilares retos com 30N de torque foram parafusados. Por sua vez, 6 implantes por grupo passaram por 500.000 ciclos de carregamento dinâmico; posteriormente, o espaço da interface do implante de pilar em 3 pontos de todas as amostras foi avaliado pelo MEV, as médias dos resultados de cada amostra foram suportadas em tabelas Excel e analisadas no programa BioEstat 5.3. Resultados: Usando um teste T para amostras independentes, com significância de 95%, foi encontrada uma diferença muito significativa após a aplicação da carga dinâmica nos implantes hexagonais externos (p = 0,0002). Nos implantes hexagonais internos também houve diferença estatística (p = 0,03). Entre os implantes hexágono externo e interno, houve diferenças muito significativas na precisão do ajuste na interface do implante de pilar antes e após a aplicação das cargas dinâmicas (p = <0,0001 ep = 0,0003, respectivamente). Conclusões: As cargas dinâmicas aumentaram significativamente a discrepância na conexão implante-pilar dos implantes hexágono externo e interno (p = <0,05); além disso, a distância do gap foi maior para os implantes hexagonais externos, em contraste com os implantes de hexágono interno antes e após o carregamento dinâmico, sendo muito significativa (p = <0,0003).


Asunto(s)
Implantes Dentales , Ajuste de Prótesis , Filtración Dental , Diseño de Dentadura , Implantación de Prótesis
12.
Salud ment ; Salud ment;42(5): 251-256, Sep.-Oct. 2019. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1094456

RESUMEN

Abstract Introduction Systemic administration of pentylenetetrazole (PTZ) causes brain damage (BD), and triggers a series of morphological and neurochemical changes, which in turn bring about behavioral, cognitive, and motor deficits. Serotonin (5-HT), dopamine (DA), and noradrenaline (NA) levels are controlled by various brain structures and these levels are related to motor activity; however, the concentration of these neurotransmitters during the postictal process remains unknown. Objective We investigated the concentration of 5-HT, NA and DA in the hippocampus, cerebellum, and cortex on motor deficit during the postictal stage. Method Eighteen male Wistar rats (300 g) assigned to two groups: control (n = 9, saline solution) and experimental (n = 9, PTZ) were used. Myoclonic shakes were counted and motor behavior assessments were recorded during three hours post PTZ injection (90 mg/kg). The cortex, cerebellum, and hippocampus of each rat were dissected to determine the 5-HT, DA, and NA concentration by high performance liquid chromatography. Results PTZ induced a significant increase in total 5-HT and DA levels in the hippocampus and cortex; in the cerebellum there was a significant increase in the concentration of 5-HT and NA. The presence of myoclonic shakes as well as a marked motor deficit in the experimental group were significantly different in comparison to the control. Discussion and conclusion 5-HT modifies the concentration of other monoamines directly involved in motor aspects such as NA and DA in the hippocampus, cerebellum, and cortex during the postictal process.


Resumen Introducción La administración sistémica de pentilentetrazol (PTZ) causa daño cerebral y desencadena una serie de cambios morfológicos y neuroquímicos que a su vez provocan déficits conductuales, cognitivos y motores. Los niveles de serotonina (5-HT), dopamina (DA) y noradrenalina (NA) son modulados por varias estructuras cerebrales y sus concentraciones se relacionan con la actividad motora; sin embargo, se desconoce la concentración de estos neurotransmisores durante el proceso postictal. Objetivo Evaluar la manera en que la concentración de 5-HT, NA y DA en el hipocampo, el cerebelo y la corteza influye en el déficit motor durante la etapa postictal. Método Se utilizaron 18 ratas macho Wistar (300 g), divididas en dos grupos: control (n = 9, solución salina) y experimental (n = 9, PTZ). Se registraron las sacudidas mioclónicas y se evaluó el comportamiento motor durante tres horas después de la inyección de PTZ (90 mg/kg). Se extrajeron la corteza, el cerebelo y el hipocampo de cada rata para determinar la concentración de 5-HT, DA y NA mediante cromatografía líquida de alta resolución. Resultados La administración de PTZ indujo un aumento significativo en los niveles totales de 5-HT y DA en el hipocampo y la corteza; en el cerebelo hubo un aumento significativo en la concentración de 5-HT y NA. Se encontró una diferencia significativa entre el grupo experimental y control con respecto a las sacudidas mioclónicas; asimismo, los animales del grupo experimental mostraron un marcado déficit motor. Discusión y conclusión La 5-HT modula la concentración de otras monoaminas involucradas directamente en aspectos motores tal como NA y DA en el hipocampo, el cerebelo y la corteza durante el proceso postictal.

13.
Ann Hepatol ; 18(1): 144-154, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31113584

RESUMEN

INTRODUCTION AND AIMS: Alcoholic hepatitis is the most severe manifestation of alcoholic liver disease. Unfortunately, there are still some unresolved issues in the diagnosis and management of this disease, such as the need of histological diagnosis, an accurate prognostic stratification, and the development of novel targeted therapies. The present study aimed at addressing these issues by means of metabolomics, a novel high-throughput approach useful in other liver diseases. MATERIAL AND METHODS: 64 patients with biopsy-proven alcoholic hepatitis were included and compared with 26 patients with decompensated alcoholic cirrhosis without superimposed alcoholic hepatitis, which was ruled out by liver biopsy. RESULTS: The comparison of the metabolic profiles of patients with alcoholic hepatitis and decompensated cirrhosis showed marked differences between both groups. Importantly, metabolic differences were found among alcoholic hepatitis patients when subjects were stratified according to 90-day survival. Based on these findings, two non-invasive signatures were developed. The first one allowed an accurate non-invasive diagnosis of alcoholic hepatitis (AUROC 0.932; 95% CI 0.901-0.963). The second signature showed a good performance in the prognostic stratification of patients with alcoholic hepatitis (AUROC 0.963; 95% CI 0.895-1.000). CONCLUSIONS: Signatures based on metabolomics allowed an accurate non-invasive diagnosis and prognostic stratification of alcoholic hepatitis. The differences observed in the metabolic profile of the patients according to the presence and severity of alcoholic hepatitis are related with different mechanisms involved in the pathophysiology of alcoholic hepatitis such as peroxisomal activity, synthesis of inflammatory mediators or oxidation. This information could be useful for the development of novel targeted therapies.


Asunto(s)
Hepatitis Alcohólica/diagnóstico , Lipidómica/métodos , Lípidos/análisis , Hígado/patología , Biomarcadores/análisis , Biopsia , Cromatografía Líquida de Alta Presión , Femenino , Estudios de Seguimiento , Hepatitis Alcohólica/sangre , Hepatitis Alcohólica/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Reproducibilidad de los Resultados , Estudios Retrospectivos , España/epidemiología , Tasa de Supervivencia/tendencias
14.
Ann Hepatol ; 18(3): 518-535, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31053546

RESUMEN

Alcohol-related liver disease (ALD) is a major cause of advanced chronic liver disease in Latin-America, although data on prevalence is limited. Public health policies aimed at reducing the alarming prevalence of alcohol use disorder in Latin-America should be implemented. ALD comprises a clinical-pathological spectrum that ranges from steatosis, steatohepatitis to advanced forms such as alcoholic hepatitis (AH), cirrhosis and hepatocellular carcinoma. Besides genetic factors, the amount of alcohol consumption is the most important risk factor for the development of ALD. Continuous consumption of more than 3 standard drinks per day in men and more than 2 drinks per day in women increases the risk of developing liver disease. The pathogenesis of ALD is only partially understood and recent translational studies have identified novel therapeutic targets. Early forms of ALD are often missed and most clinical attention is focused on AH, which is defined as an abrupt onset of jaundice and liver-related complications. In patients with potential confounding factors, a transjugular biopsy is recommended. The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed. In both patients with early and severe ALD, prolonged abstinence is the most efficient therapeutic measure to decrease long-term morbidity and mortality. A multidisciplinary team including alcohol addiction specialists is recommended to manage patients with ALD. Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy.


Asunto(s)
Consumo de Bebidas Alcohólicas/efectos adversos , Gastroenterología , Hepatopatías Alcohólicas/epidemiología , Guías de Práctica Clínica como Asunto , Sociedades Médicas , Consumo de Bebidas Alcohólicas/epidemiología , Humanos , América Latina/epidemiología , Prevalencia , Factores de Riesgo
15.
Hepatology ; 69(5): 1916-1930, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30324707

RESUMEN

Risk of alcoholic cirrhosis is determined by genetic and environmental factors. We aimed to investigate if climate has a causal effect on alcohol consumption and its weight on alcoholic cirrhosis. We collected extensive data from 193 sovereign countries as well as 50 states and 3,144 counties in the United States. Data sources included World Health Organization, World Meteorological Organization, and the Institute on Health Metrics and Evaluation. Climate parameters comprised Koppen-Geiger classification, average annual sunshine hours, and average annual temperature. Alcohol consumption data, pattern of drinking, health indicators, and alcohol-attributable fraction (AAF) of cirrhosis were obtained. The global cohort revealed an inverse correlation between mean average temperature and average annual sunshine hours with liters of annual alcohol consumption per capita (Spearman's rho -0.5 and -0.57, respectively). Moreover, the percentage of heavy episodic drinking and total drinkers among population inversely correlated with temperature -0.45 and -0.49 (P < 0.001) and sunshine hours -0.39 and -0.57 (P < 0.001). Importantly, AAF was inversely correlated with temperature -0.45 (P < 0.001) and sunshine hours -0.6 (P < 0.001). At a global level, all included parameters in the univariable and multivariable analysis showed an association with liters of alcohol consumption and drinkers among population once adjusted by potential confounders. In the multivariate analysis, liters of alcohol consumption associated with AAF. In the United States, colder climates showed a positive correlation with the age-standardized prevalence of heavy and binge drinkers. Conclusion: These results suggest that colder climates may play a causal role on AAF mediated by alcohol consumption.


Asunto(s)
Consumo de Bebidas Alcohólicas/efectos adversos , Clima Frío/efectos adversos , Cirrosis Hepática Alcohólica/epidemiología , Consumo de Bebidas Alcohólicas/epidemiología , Estudios Transversales , Humanos , Internacionalidad , Cirrosis Hepática Alcohólica/etiología , Luz Solar , Estados Unidos/epidemiología
16.
Pharmacol Rep ; 70(2): 385-389, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29477948

RESUMEN

BACKGROUND: Levetiracetam (LEV) is a novel anticonvulsant with proven antinociceptive properties. However, the antinociceptive and pronociceptive effect of this drug has not yet been fully elucidated in a tonic pain model. METHODS: Thirty-six male rats (Wistar) were randomized into six groups and underwent the formalin test as follows: rats in the control group were administered 50µL of 1% formalin in the paw; sham-group rats were administered 50µL of saline in the paw to mimick the application of formalin; the four experimental groups were administered LEV intragastrically (ig) (50, 100, 200 and 300mg/kg), and 40min later 50µL of 1% formalin was injected in the paw. RESULTS: LEV exhibited antinociceptive effect in the 300mg/kg LEV group (p<0.05) and a pronociceptive effect in the 100mg/kg LEV group (p<0.05) and in the 50mg/kg LEV group (p<0.001). CONCLUSIONS: The antinociceptive and pronociceptive effect of LEV in a tonic pain model is dose-dependent.


Asunto(s)
Anticonvulsivantes/farmacología , Nocicepción/efectos de los fármacos , Dolor/tratamiento farmacológico , Piracetam/análogos & derivados , Analgésicos/farmacología , Animales , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Levetiracetam , Masculino , Dimensión del Dolor/métodos , Piracetam/farmacología , Ratas , Ratas Wistar
17.
Curr Neuropharmacol ; 16(2): 210-221, 2018 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-28901281

RESUMEN

BACKGROUND: The aim of this review was to identify the mechanisms by which serotonin receptors involved at the central level are able to modulate the nociceptive response. Pain is a defense mechanism of the body that entails physiological, anatomical, neurochemical, and psychological changes, and is defined as an unpleasant sensory and emotional experience with potential risk of tissue damage, comprising the leading cause of appointments with Physicians worldwide. Treatment for this symptom has generated several neuropharmacological lines of research, due to the different types of pain and the various drugs employed to treat this condition. Serotonin [5- HydroxyTryptamine (5-HT)] is a neurotransmitter with seven families (5-HT1-5-HT7) and approximately 15 receptor subtypes. Serotonin modulates neuronal activity; however, this neurotransmitter is related with a number of physiological processes, such as cardiovascular function, gastric motility, renal function, etc. On the other hand, several researches reported that serotonin modulates nociceptive response through 5-HT1, 5-HT2, 5-HT3, and 5-HT7 receptors in the Central Nervous System (CNS). METHOD: In this review, a search was conducted on PubMed, ProQuest, EBSCO, and the Science Citation Index for studies evaluating the effects of 5-HT1, 5-HT2, 5-HT3, and 5-HT7 receptors in the CNS on the modulation of different types of pain. CONCLUSION: We concluded that 5-HT1, 5-HT2, 5-HT3, and 5-HT7 receptors in the CNS modulate the pain, but this depends on the distribution of the receptors, dose of agonists or antagonists, administration route, pain type and duration in order to inhibit, excite, or even maintain the nociceptive response.


Asunto(s)
Analgésicos/uso terapéutico , Sistema Nervioso Central/metabolismo , Dolor , Receptores de Serotonina/metabolismo , Analgésicos/farmacología , Animales , Sistema Nervioso Central/efectos de los fármacos , Humanos , Dolor/tratamiento farmacológico , Dolor/metabolismo , Dolor/patología , Serotonina/metabolismo
18.
Am J Gastroenterol ; 112(2): 306-315, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27922027

RESUMEN

OBJECTIVES: Prednisolone therapy increases the risk of infections in patients with severe alcoholic hepatitis (SAH). We evaluated whether the use of the Lille Model at day 4 (LM4) is useful to predict response to prednisolone compared with the classic day 7 (LM7) in order to limit a futile exposure to corticosteroids. METHODS: We performed a retrospective analysis of a large multinational cohort of patients with SAH with Maddrey's discriminant function (DF) ≥32. Response to corticosteroids was assessed with LM4 and LM7, according to the validated cutoff value (CUV>0.45). Receiver operating characteristics (ROC) curves were constructed to determine the optimal CUV for LM4 and to compare accuracy between LM4, LM7, MELD (Model for End-Stage Liver Disease), and ABIC (age, bilirubin, international normalized ratio, and creatinine). Logistic regression models were constructed to predict 28- and 90-day mortality. Cox regression analysis was performed to assess long-term survival. RESULTS: A total of 163 (62.7%) out of 260 patients received corticosteroids. The median DF for the patients treated with corticosteroids was 64.1 (47.9-81.3). Overall 90-day mortality was 35.9%. The median LM4 and LM7 for the patients who received treatment was 0.39 (0.19-0.83) and 0.36 (0.13-0.77). LM4 was a strong independent predictor of 28-day mortality (OR 25.4, (95% confidence interval (CI) 5.1-126.8), P<0.001). By using LM4 with a CUV>0.45, 28- and 90-day survival was significantly higher for responders (90% and 76%) than non-responders (66% and 40%), P<0.001. Importantly, the area under the ROC curve for predicting mortality for LM4 was similar than the classic LM7 (0.77 vs. 0.75, respectively: P=0.558). CONCLUSIONS: LM4 is as accurate as LM7 in predicting response to corticosteroids, as well as 28- and 90-day mortality. Assessing the efficacy of prednisolone at an earlier time point can avoid a more prolonged futile use of this therapy.


Asunto(s)
Glucocorticoides/uso terapéutico , Hepatitis Alcohólica/tratamiento farmacológico , Prednisolona/uso terapéutico , Adulto , Factores de Edad , Bilirrubina/sangre , Brasil , Estudios de Casos y Controles , Estudios de Cohortes , Creatinina/sangre , Análisis Discriminante , Enfermedad Hepática en Estado Terminal , Femenino , Hepatitis Alcohólica/sangre , Hepatitis Alcohólica/mortalidad , Humanos , Relación Normalizada Internacional , Modelos Logísticos , Masculino , Persona de Mediana Edad , Pronóstico , Modelos de Riesgos Proporcionales , Curva ROC , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , España , Resultado del Tratamiento , Estados Unidos
19.
Ann Hepatol ; 15(6): 895-901, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27740523

RESUMEN

Background. The Rockall, Glasgow-Blatchford, and AIMS65 are useful and validated scoring systems for predicting the outcomes of patients with nonvariceal gastrointestinal bleeding. However, there are no validated evidence for using them to predict outcomes on variceal bleeding. The aim of this study was to evaluate and compare the prognostic accuracy of different nonvariceal bleeding scores with other liver-specific scoring systems in cirrhotic patients. MATERIAL AND METHODS: A retrospective multicenter study that included 160 cirrhotic patients with acute variceal bleeding. The AUROC's to predict in-hospital mortality, and rebleeding, were analyzed for each scoring system. RESULTS: Overall in-hospital mortality occurred in 13% and in-hospital rebleeding in 12% of patients. The systems with the best AUROC value for predicting mortality were MELD (0.828; 95% CI 0.748-0.909), and AIMS65 (0.817; 95% CI 0.724-0.909). The best score systems for predicting rebleeding were Glasgow-Blatchford (0.756; 95% CI 0.640- 0.827), and Rockall (0.691; 95% CI 0.580-0.802). CONCLUSIONS: In addition to liver-specific scores, the AIMS65 score is accurate for predicting in-hospital mortality in cirrhotic patients with acute variceal bleeding. Other scoring systems might be useful for predicting significant clinical outcomes in these patients.


Asunto(s)
Técnicas de Apoyo para la Decisión , Várices Esofágicas y Gástricas/etiología , Hemorragia Gastrointestinal/etiología , Cirrosis Hepática/complicaciones , Adulto , Anciano , Área Bajo la Curva , Várices Esofágicas y Gástricas/diagnóstico , Várices Esofágicas y Gástricas/mortalidad , Femenino , Hemorragia Gastrointestinal/diagnóstico , Hemorragia Gastrointestinal/mortalidad , Mortalidad Hospitalaria , Humanos , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/mortalidad , Masculino , México , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Curva ROC , Recurrencia , Reproducibilidad de los Resultados , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo
20.
Ann Hepatol ; 15(4): 463-73, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27236145

RESUMEN

 The burden of alcoholic liver disease continues to be a major public health problem worldwide. The spectrum of disease ranges from fatty liver to cirrhosis and hepatocellular carcinoma. Alcoholic hepatitis (AH) is a type of acute-on-chronic liver failure and the most severe form of alcoholic liver disease. Severe AH carries a poor short-term prognosis and its management is still challenging, with scarce advances in the last decades. Corticosteroids are still the first line of therapy in severe cases. Unfortunately, many patients do not respond and novel targeted therapies are urgently needed. Liver transplantation has shown extraordinary results in non-responders to corticosteroids however; its applicability is very low. This review summarizes the epidemiology, natural history, risk factors and pathogenesis of alcoholic liver disease with special focus on the latest advances in prognostic stratification and therapy of patients with alcoholic hepatitis.


Asunto(s)
Insuficiencia Hepática Crónica Agudizada/fisiopatología , Hígado Graso Alcohólico/fisiopatología , Hepatitis Alcohólica/fisiopatología , Insuficiencia Hepática Crónica Agudizada/epidemiología , Insuficiencia Hepática Crónica Agudizada/terapia , Corticoesteroides/uso terapéutico , Hígado Graso Alcohólico/epidemiología , Hígado Graso Alcohólico/terapia , Hepatitis Alcohólica/epidemiología , Hepatitis Alcohólica/terapia , Humanos , Cirrosis Hepática Alcohólica/epidemiología , Cirrosis Hepática Alcohólica/fisiopatología , Cirrosis Hepática Alcohólica/terapia , Trasplante de Hígado , Pronóstico , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA